Dasatinib is a targeted cancer therapy (a tyrosine kinase inhibitor) used to treat forms of leukemia, such as chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL). Clinical data indicates that lower-strength dosing may be employed, which can be associated with higher tolerability in certain patients.Dosage and AdministrationUsage: Used for newly diagnosed Ph+ CML in the chronic phase, as well as in patients resistant or intolerant to prior therapies.Guidelines: It is usually taken once daily at the same time, with or without food. Tablets must be swallowed whole and should not be split, crushed, or chewed. Avoid taking antacids within 2 hours of your dose.Safety: If side effects like pleural effusion (fluid around the lungs) occur, your oncologist may temporarily pause treatment or adjust your dosage.Important Safety InformationCommon Side Effects: Nausea, diarrhea, headache, muscle pain, fatigue, rash, and low blood cell counts (thrombocytopenia, anemia).Monitoring: Regular blood tests are necessary to check your blood counts and monitor your liver/heart function.Warnings: Dasatinib is unsafe during pregnancy and may cause toxicity to the developing baby.Always consult your hematologist or oncologist for the exact dosing schedule tailored to your specific condition and treatment plan. Detailed prescribing information is available through the MedlinePlus Drug Information guide.